Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III

Principal Investigator

Project Staff

Institute Presentation

The Spanish National Cancer Centre (CNIO) was founded in 1998 by the Carlos III Institute of Health. Is one of the few European Cancer Centres to allocate resources to both basic and applied research, supporting the interaction of basic research programmes with those of molecular diagnostics and drug discovery. CNIO provides the infrastructure to support a wide range of research, from structural analysis of molecules (NMR, X-ray Crystallography), Microscopy (conventional, fluorescence, confocal, etc.), the latest technology available in the field of cytogenetics, OMICs platforms, immunohistochemistry (Tissue Arrays), next generation sequencers, or generations of transgenic mice. Dr. Robledo’s group has a long experience on molecular diagnosis of hereditary cancer, and currently is one of the recognized reference groups in PCC/PGL molecular characterization in Spain. Expertise in OMICs approaches will be applied to identify transcriptome, mirnome, methylome and CGH profiles of PCC/PGL specimens, not only already available but also prospectively collected through the collaboration of the CNIO Tumour Bank Network and other teams participating in the Consortium.
Dr. Mercedes Robledo is member of the Spanish Human Genetics Association, and member of the Evaluation Committee of National Projects from the Spanish Health Ministry, reviewer of European Projects; her group is the Spanish Reference centre for the molecular study of Pheochromocytomas and Paragangliomas, among other hereditary tumoural endocrine syndromes.

CNIO participates in WP4. The main tasks will consist of

• identification of biomarkers related to malignant behaviour in PCC and PGLs by using OMIC approaches,
• validation of markers on alternative tumours set, as well as
• identification of new markers related to treatment response.